Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Aldeyra Therapeutics Q3 2026 Results: Net Loss of $3.76M, Loss Narrows

Aldeyra Therapeutics reported a net loss of $3.8 million for the third quarter of 2026, a significant reduction from the $7.7 million loss in the same period of 2025, primarily driven by lower research and development expenses. The company's cash position decreased to $41.0 million as of September 30, 2026, following the full repayment of its $15.0 million long-term debt during the year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-3.8-7.7
EPS (diluted, $ a share)$-0.06$-0.13

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ALDX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Aldeyra Therapeutics, Inc.: key numbers

Share price
$0.6696Close, Nov 16
Market cap
$40.4M
Shares outstanding
60.36MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Aldeyra Therapeutics, Inc.

All →
4:27 PM ET Form 4
Insider Buying

Aldeyra Therapeutics Director Richard Douglas Buys $129K of Stock

Richard Douglas, Director, bought 200,000 shares of Aldeyra Therapeutics, Inc. at $0.6445 a share, worth $129K in total on Nov 11, 2026. Shares held after the trade: 395,000 (+102.6%).

Value
$129K
Shares
200,000
Price
$0.6445
Role
Director
Holding change
+102.6%
Trade date
Nov 11, 2026
4:02 PM ET 8-K
Business Update

Aldeyra Therapeutics Business Update

Aldeyra Therapeutics has requested that the FDA transfer the review jurisdiction of its ADX-2191 IND for primary vitreoretinal lymphoma from the Division of Ophthalmology to the Division of Hematologic Malignancies 2. In connection with this request, the company has withdrawn its previously agreed-upon Special Protocol Assessment (SPA) protocol, creating uncertainty and potential delays in the clinical development timeline for the candidate.

Counterparty
FDA
7:01 AM ET 8-K
Investor Presentation

Aldeyra Therapeutics Investor Presentation

Aldeyra Therapeutics announced its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA appealing a prior Complete Response Letter for reproxalap in dry eye disease. The company also extended its projected cash runway into 2029 and filed a formal supplemental presentation detailing the regulatory update and upcoming meeting with the FDA's Office of New Drugs.

Counterparty
FDA

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.